靶向TROP-2阳性癌症的嵌合抗原受体
本发明的实施方案包括与用特定改造的受体靶向表达TROP‑2的细胞相关的方法和组合物。在特定实施方案中，使用特定的嵌合抗原受体构建体特异性改造NK细胞以使其结合TROP‑2。在某些实施方案中，表达靶向TROP‑2的CAR的载体也表达特定的自杀基因和/或一种或多种特定的细胞因子。.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 12. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Chinesisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-04-12, Last update posted on www.tib.eu: 2024-05-07, Last updated: 2024-05-10 |
|---|
| Patentnummer: |
CN117881407 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003810038 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003810038 | ||
| 003 | DE-627 | ||
| 005 | 20240510112346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240426s2024 xx |||||o 00| ||chi c | ||
| 035 | |a (DE-627)EPA003810038 | ||
| 035 | |a (EPA)CN117881407 | ||
| 035 | |a (EPA)84802126 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 245 | 1 | 0 | |a 靶向TROP-2阳性癌症的嵌合抗原受体 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-04-12, Last update posted on www.tib.eu: 2024-05-07, Last updated: 2024-05-10 | ||
| 520 | |a 本发明的实施方案包括与用特定改造的受体靶向表达TROP‑2的细胞相关的方法和组合物。在特定实施方案中，使用特定的嵌合抗原受体构建体特异性改造NK细胞以使其结合TROP‑2。在某些实施方案中，表达靶向TROP‑2的CAR的载体也表达特定的自杀基因和/或一种或多种特定的细胞因子。 | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 12. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84802126/publication/CN117881407A1?q=CN117881407 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 04 | ||